Skip to main content

Immunicum AB (publ) Completes Business Combination with DCprime

Written by Customer Service on . Posted in Public Companies.

Press Release21 December 2020Immunicum AB (publ) Completes Business Combination with DCprimeImmunicum AB (publ; IMMU.ST) (“Immunicum” or the “Company”) today completed the business combination with DCPrime BV, a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence, via the acquisition of all shares in DCPrime BV. In accordance with previous communication, the purchase price consists of 73,909,635 newly issued shares in Immunicum.“This marks the achievement of a major turning point for Immunicum on its trajectory toward becoming a fully-integrated biopharmaceutical company,” commented Michael Oredsson, Chairman of the Board of Directors at Immunicum. “We would therefore like to thank the teams at Immunicum and DCprime, our advisors and our shareholders for supporting us during the transaction process. We look forward to further establishing and advancing this newly-merged company built on decades of combined immuno-oncology and cell therapy expertise in the field of allogeneic dendritic cell biology.”Completion of the Combination with DCprime
On 18 November 2020, Immunicum announced that it had entered into an agreement with Van Herk Investments BV to acquire all shares in DCPrime BV (the “Transaction”) through an issue in kind of 73,909,635 new shares in Immunicum, corresponding to 44 percent of the total number of shares in Immunicum on a fully diluted basis.The Extraordinary General Meeting on 18 December 2020 resolved to approve the Board’s decision of 18 November 2020 on a directed new issue of shares to Van Herk against payment with capital contributed in kind consisting of all shares in DCprime. As of today’s date, the combination has been completed according to the previously communicated time schedule, and Immunicum has obtained all shares in DCPrime BV.The directed issue implies that the Company’s share capital will increase by SEK 3,695,481.75 through a new issue of 73,909,635 shares, which corresponds to a dilution of 44.48 percent (44.0 percent on a fully diluted basis considering outstanding warrants).Prior to the completion of the Transaction, Van Herk acquired the minority shareholders’ shares in DCPrime BV. The minority shareholders have partly been paid in cash and partly in newly issued shares that Van Herk is receiving in Immunicum. As a result of the Transaction, Van Herk is the largest shareholder in Immunicum with a shareholding of approximately 43 percent of the total number of outstanding shares after the Transaction and after the transfer of newly issued shares to the minority shareholders.For more information on the Transaction, please refer to Immunicum’s previous press release on 18 November 2020 and 8 December 2020.Financial and Legal Advisors
Erik Penser Bank is acting as financial advisor, Asperion is acting as strategic advisor and Advokatfirman Delphi is legal advisor to Immunicum in relation to the Transaction. Kempen & Co is acting as financial advisor and Advokatfirman Cederquist and Allen & Overy are acting as legal advisors to DCprime.The information was submitted for publication, through the agency of the contact person set out below on December 21, 2020, at 4:00 pm CET.
FOR MORE INFORMATION, PLEASE CONTACT:Sven Rohmann, CEO, MD, Ph.D.
Telephone: +46 8 732 8400
E-mail: info@immunicum.com INVESTOR RELATIONSJonas Rodny and Carolin Wiken
Paues Åberg Communications
Telephone: +46 76 190 90 51
E-mail: ir@immunicum.comMEDIA RELATIONSJoanne Tudorica and Sophia Hergenhan, Ph.D.
Trophic Communications
Telephone: +49 171 351 2733
E-mail: ir@immunicum.comABOUT IMMUNICUM AB (PUBL)Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The Company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.comABOUT DCPRIMEDCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. DCprime’s product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. DCprime is pursuing similar vaccination approaches for solid tumors. DCprime believes relapse vaccines will improve survival by putting the patient’s immune system back in control. For more information, please visit: https://dcprime.com/ Attachment20201221_Immunicum Completes Business Combination with DCprime_ENG_Final

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.